1. Handbook of Multiple Sclerosis;Cohen,2012
2. Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective us claims database analysis;Bergvall N;Curr. Med. Res. Opin,2014
3. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of ms patients in canada;Karampampa K;J. Popul. Ther. Clin. Pharmacol,2012
4. The burden of neurological diseases,2007
5. Multiple sclerosis in canada 2011 to 2031: results of a microsimulation modelling study of epidemiological and economic impacts;Amankwah;Chronic Dis. Inj. Can,2017